---
layout: post
title: "Revocation of Emergency Use of a Biological Product; Availability"
date: 2026-02-04 21:45:56 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-19270
original_published: 2025-10-02 00:00:00 +0000
significance: 8.00
---

# Revocation of Emergency Use of a Biological Product; Availability

**Published:** February 04, 2026 21:45 UTC
**Source:** Federal Register
**Original Published:** October 02, 2025 00:00 UTC
**Document Number:** 2025-19270

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (ASPR/HHS) for COVID-19 convalescent plasma. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/10/02/2025-19270/revocation-of-emergency-use-of-a-biological-product-availability)
- API: https://www.federalregister.gov/api/v1/documents/2025-19270

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
